Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 7/20 | 0.65 |
| ▸ | FGF1 | P05230 | 7/20 | 0.65 |
| ▸ | FGF2 | P09038 | 7/20 | 0.65 |
| ▸ | ST3GAL1 | Q11201 | 1/20 | 0.61 |
| ▸ | CDC25A | P30304 | 4/20 | 0.60 |
| ▸ | POLA1 | P09884 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.55 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23223299 | 0.96 | HPSE (0.63) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL23223301 | 0.96 | HPSE (0.63) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL21340483 | 0.94 | HPSE (0.61) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL24017768 | 0.94 | HPSE (0.61) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL24017722 | 0.94 | CDC25A (0.60) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL20004930 | 0.92 | CDC25A (0.61) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL21340268 | 0.90 | CDC25A (0.61) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL24017723 | 0.90 | CDC25A (0.61) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL23614817 | 0.83 | HPSE (0.61) | HPSEFGF1FGF2ST3GAL1CDC25A | |
| SCHEMBL3691749 | 0.82 | HPSE (0.68) | HPSEFGF1FGF2ST3GAL1CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173177-B2 | Compounds for treatment of lipoprotein metabolism disorders | AARHUS UNIVERSITET (DK) | 2021-11-16 | — | — | US | disclosed |
| US-20190275074-A1 | COMPOUNDS FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS | AARHUS UNIVERSITET (DK) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275074-A1 | COMPOUNDS FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS | PCSK9, PCSK6, PCSK7 | HPSE 31/4885FGF1 2061/4885FGF2 3196/4885 |
| US-11173177-B2 | Compounds for treatment of lipoprotein metabolism disorders | PCSK9, PCSK6, PCSK7 | HPSE 31/4885FGF1 2061/4885FGF2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.